Just in:
L’OCCITANE Celebrates 50 Years Of Provençal Craftsmanship With Holiday 2026 Collection // From Dubai to the EU: how UAE-based crypto firms can expand under MiCA // Woman found dead as bank moves to repossess home // Inpex reaffirms Gulf oil strategy despite shipping constraints // TORRAS Launches Two New iPhone Duo Cases from Its Popular Ostand Series, Addressing Foldable Phone Users’ Concerns About Difficult Stand Positioning and Scratches // Microsoft restores services gradually but gives no recovery deadline // US resumes flights after nationwide air traffic shutdown // Fujairah highway pile-up leaves 14 dead and 30 injured // China Reconciled To U.S. Curbs On Chips Exports, Woos South Korea For Supply // The Honey Trap Is The Headline, The Chip Pipeline Is The Story // IEA forecasts fourth-quarter oil surplus as Gulf shipments rebound // Saudi fund assets forecast to cross $400 billion // EBANX and Eneba strengthen partnership in Latin America with 138% YoY growth in payment volume // US authorities dismantle North Korean cryptocurrency deception infrastructure // Hackers falsify NVIDIA GPU readings to mask cryptomining // Yicura BioMed Advances Dual Capital and Industrial Strategy: Completes First Closing of Series B Financing Led by Gobi Partners // OpenAI unveils ChatGPT Wallet for agent-led purchases // Nvidia appoints Colette Kress interim chief after Huang departure // Microsoft apologises as Outlook services recover after outage // Messi affair SIT finds all-round violations //

Ranbaxy withdraws wrongly-packed medicine in US

ranbaxy headqartersDrug maker Ranbaxy Laboratories Ltd  has recalled more than 64,000 bottles of the generic versions of its cholesterol-lowering drug in the United States due to reports of a dose mix-up, U.S. regulators said.

Ranbaxy recalled tablets of atorvastatin calcium, the generic name for Lipitor’s active ingredient, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the U.S. Food and Drug Administration (FDA) said on its website.

The FDA declared a Class II recall, which signifies a remote chance of severe adverse consequences or death due to the product flaw.

Ranbaxy could not be reached for comment outside of India’s business hours.

This is at least the third recall of generic Lipitor over the past two years.

Hit by regulatory scrutiny, India’s biggest drug maker by revenue had recalled 480,000 bottles of the cholesterol fighter in November 2012 after the company discovered contamination with tiny glass particles.

Worries about quality control in India’s $14 billion drug industry have come to the fore in the past year as plants run by Ranbaxy and local rival Wockhardt Ltd  have been barred from sending drugs to the United States after falling short of the FDA’s “good manufacturing practices”.-Reuters



Notice an issue?

Arabian Post strives to deliver the most accurate and reliable information to its readers. If you believe you have identified an error or inconsistency in this article, please don't hesitate to contact our editorial team at editor[at]thearabianpost[dot]com. We are committed to promptly addressing any concerns and ensuring the highest level of journalistic integrity.


Loading next story…